GlassScriptPhysician profile
Amy Scullion
NPI 1134623655
$1,356.13
in general payments reported to CMS, 2019-2025
18 companies · $622 in 2025
The $622 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.82 · 2022: $60.98 · 2023: $52.01 · 2024: $603 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $266.74 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Abbvie INC. | $234.02 | 2021-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $132.81 | 2024-2025 | Breztri, Farxiga |
| Pfizer INC. | $132.47 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $96.54 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.38 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $76.26 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $51.26 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.08 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $41.07 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Inspire Medical Systems, INC. | $32.36 | 2025 | Inspire |
| Vertex Pharmaceuticals Incorporated | $31.02 | 2025 | |
| Glaxosmithkline, LLC. | $30.21 | 2024 | Trelegy Ellipta |
| Tactile Systems Technology INC | $24.38 | 2024 | Entre Plus, Flexitouch Plus |
| Becton, Dickinson and Company | $22.61 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.20 | 2024 | Rexulti |
| Dexcom, INC. | $18.24 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $16.48 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Scullion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.